Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080507 | 0.88 | MAPT (0.41) | MAPTCYP3A4BLMPMP22MAPK1 | |
| SCHEMBL2079989 | 0.85 | MAPK1 (0.39) | MAPTCYP3A4BLMPMP22MAPK1 | |
| SCHEMBL3434169 | 0.82 | MAPK1 (0.47) | MAPTMAPK1ALDH1A1LMNACYP2C9 | |
| SCHEMBL3435589 | 0.80 | GAA (0.43) | MAPTCYP3A4ALDH1A1SMN1; SMN2CYP2C9 | |
| SCHEMBL3435979 | 0.80 | MAPK1 (0.42) | MAPTCYP3A4BLMPMP22MAPK1 | |
| SCHEMBL3436159 | 0.80 | MAPT (0.61) | MAPTCYP3A4BLMPMP22MAPK1 | |
| SCHEMBL3436488 | 0.79 | CYP1A2 (0.42) | MAPTCYP3A4ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3434236 | 0.79 | MAPK1 (0.43) | MAPTMAPK1ALDH1A1LMNACYP2C9 | |
| SCHEMBL3435531 | 0.78 | ALDH1A1 (0.45) | MAPTCYP3A4BLMPMP22MAPK1 | |
| SCHEMBL3435981 | 0.78 | MAPT (0.52) | MAPTCYP3A4BLMPMP22MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | MAPT 1330/4885CYP3A4 1991/4885BLM 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.